1. null
    Gianfranco Natale et al, 2017 CrossRef
  2. Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology
    Eddy Pasquier et al, 2011, Translational Oncology CrossRef
  3. Novel isatin derivatives of podophyllotoxin: synthesis and cytotoxic evaluation against human leukaemia cancer cells as potent anti-MDR agents
    Lei Zhang et al, 2015, RSC Adv. CrossRef
  4. Etoposide-Loaded Poly(Lactic-co-Glycolic Acid) Intravitreal Implants: In Vitro and In Vivo Evaluation
    Ana Gabriela Reis Solano et al, 2018, AAPS PharmSciTech CrossRef
  5. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
    Gianfranco Natale et al, 2018, Cancer Letters CrossRef
  6. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.
    Behrouz Hassannia et al, 2018, J Clin Invest CrossRef
  7. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma
    C. K. Alexander et al, 2018, J Small Anim Pract CrossRef
  8. Tumor endothelial cells as a potential target of metronomic chemotherapy
    Ji Yoon Kim et al, 2019, Arch. Pharm. Res. CrossRef
  9. Successful treatment of metastatic cerebral recurrence of pleuropulmonary blastoma
    Yoshiko Nakano et al, 2019, Pediatr Blood Cancer CrossRef
  10. null
    Ella Fremder et al, 2014 CrossRef
  11. Regulation of inflammation in cancer by eicosanoids
    Emily R. Greene et al, 2011, Prostaglandins & Other Lipid Mediators CrossRef
  12. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis
    PER ALBERTSSON et al, 2012 CrossRef
  13. Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy
    Randi Nygaard et al, 2012, Anti-Cancer Drugs CrossRef
  14. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
    Andreas Peyrl et al, 2012, Pediatr. Blood Cancer CrossRef
  15. Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)
    Manikandan Dhanushkodi et al, 2019, Indian J Gynecol Oncolog CrossRef
  16. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
    Nathan J. Robison et al, 2014, Pediatr Blood Cancer CrossRef
  17. High Throughput Screening of Natural Products for Anti-mitotic Effects in MDA-MB-231 Human Breast Carcinoma Cells
    E. Mazzio et al, 2014, Phytother. Res. CrossRef
  18. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma
    Grace Kong et al, 2016, Journal of Pediatric Hematology/Oncology CrossRef
  19. Novel Etoposide Analogue Modulates Expression of Angiogenesis Associated microRNAs and Regulates Cell Proliferation by Targeting STAT3 in Breast Cancer
    Chatla Srinivas et al, 2015, PLoS ONE CrossRef
  20. Chemotherapy and Hormone Refractory Advanced Breast Cancer: Excellent Response to Oral Etoposide
    Manikandan Dhanushkodi et al, 2019, Indian J Gynecol Oncolog CrossRef
  21. Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.
    Simone Treiger Sredni et al, 2017, Oncotarget CrossRef
  22. Chimiothérapie métronomique en 2011 : actualités et perspectives
    Zineb Benbrahim et al, 2011, Bulletin du Cancer CrossRef
  23. Sequential Treatment of Bioresponsive Nanoparticles Elicits Antiangiogenesis and Apoptosis and Synergizes with a CD40 Agonist for Antitumor Immunity
    Xiang Ling et al, 2020, ACS Nano CrossRef
  24. Cytoreductive Chemotherapy Improves the Biodistribution of Antibodies Directed against Tumor Necrosis in Murine Solid Tumor Models
    Julie K. Jang et al, 2013, Mol Cancer Ther CrossRef
  25. Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
    Tooba A. Cheema et al, 2011, Clin Cancer Res CrossRef
  26. Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow
    Mary F. McGuire et al, 2013, Cancer Res CrossRef
  27. GT198 Is a Target of Oncology Drugs and Anticancer Herbs
    Junfeng Pang et al, 2021, Front. Oral. Health CrossRef
  28. Vitamin D3/phospholipid complex decorated caseinate nanomicelles for targeted delivery of synergistic combination therapy in breast cancer
    Mona M. Agwa et al, 2021, International Journal of Pharmaceutics CrossRef
  29. Innovative therapy concepts for pediatric brain tumors
    Amedeo A. Azizi et al, 2021, memo CrossRef
  30. Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
    Marina Pagnuzzi-Boncompagni et al, 2021, Cancers CrossRef
  31. Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment
    Rebecca M. Hill et al, 2021, Cancers CrossRef
  32. IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR
    Junfei Han et al, 2022, Front. Cell Dev. Biol. CrossRef
  33. null
    Samudyata C. Prabhuswamimath, 2022 CrossRef
  34. Novel Pharmacological Treatment Options in Pediatric Glioblastoma—A Systematic Review
    Johanna Wyss et al, 2022, Cancers CrossRef
  35. Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach
    Irene Slavc et al, 2022, Cancers CrossRef
  36. A liposomal etoposide with a sustained drug release effectively alleviated the therapy-related leukemia
    Yan Xiong et al, 2023, International Journal of Pharmaceutics CrossRef
  37. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen
    Andreas Peyrl et al, 2023, JAMA Oncol CrossRef
  38. Nanocrystal-Loaded Lipid Carriers for Improved Oral Absorption and Anticancer Efficacy of Etoposide: Formulation Development, Transport Mechanism, In Vitro and In Vivo Evaluation
    Yue Wang et al, 2024, Mol. Pharmaceutics CrossRef